Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Axl-DM1 mAb ADC
- Development stage
- Preclinical
- Lead developer
- National Research Council of Canada
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Axl-DM1 mAb ADC is a preclinical antibody-drug conjugate (ADC) developed by the National Research Council of Canada. It consists of a conventional monoclonal antibody (mAb) targeting the extracellular domain of the receptor tyrosine kinase AXL (Anexelekto), conjugated to the microtubule-disrupting cytotoxic payload DM1 (emtansine) via a non-cleavable linker. AXL is an oncogenic target upregulated in various cancers, including breast, lung, ovarian, gastric, and prostate cancers, and is associated with epithelial-to-mesenchymal transition, metastasis, and drug resistance. In preclinical studies, Axl-DM1 mAb ADC demonstrated sub-nanomolar cytotoxic potency in vitro against AXL-expressing breast, lung, and ovarian cancer cell lines, and showed potent anti-tumor activity in vivo in ovarian and breast cancer xenograft models.
- Other names
- Axl-DM1 ADCAxl-DM-1 ADCAxl-DM 1 ADCanti-AXL-DM1 ADCanti-AXL-DM-1 ADCanti-AXL-DM 1 ADCanti-AXL-DM1 conjugateanti-AXL-DM-1 conjugateanti-AXL-DM 1 conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on Axl-DM1 mAb ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axl-DM1 mAb ADC.